Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Converting enzyme inhibitors

Folic acid deficiency Hyperthermia Phenylketonuria Rheumatic disease Virilizing tumors Drugs and chemicals Androgenic chemicals Angiotensin-converting enzyme inhibitors Captopril, enalapril Antibiotics... [Pg.314]

ACE inhibitors inhibit the degradation of bradykinin and potentiate the effects of bradykinin by about 50-100-fold. The prevention of bradykinin degradation by ACE inhibitors is particularly protective for the heart. Increased bradykinin levels prevent postischemic reperfusion arrhythmia, delays manifestations of cardiac ischemia, prevents platelet aggregation, and probably also reduces the degree of arteriosclerosis and the development of cardiac hypertrophy. The role of bradykinin and bradykinin-induced NO release for the improvement of cardiac functions by converting enzyme inhibitors has been demonstrated convincingly with use of a specific bradykinin receptor antagonist and inhibitors of NO-synthase. [Pg.10]

Most ACE inhibitors are prodrugs, with the exceptions of captopril, lisinopril, and ceranapril. Prodrugs exert improved oral bioavailability, but need to be converted to active compounds in the liver, kidney, and/or intestinal tract. In effect, converting enzyme inhibitors have quite different kinetic profiles with regard to half time, onset and duration of action, or tissue penetration. [Pg.11]

Gohlke P, Unger T (1994) Angiotensin converting enzyme inhibitors, Chap. 65. In Swales ID (ed) Textbook of hypertension. Blackwell Scientific Publications, Oxford, London, Edinburgh, pp 1115-1127... [Pg.11]

Wong J, Patel RA, Kowey PR (2004) The clinical use of angiotensin-converting enzyme inhibitors. Prog. Cardiovasc. Dis. 47, 116-130... [Pg.11]

Stumpf JL. Shehab N. Patel AC Safety of angiotensin-converting enzyme inhibitors in patients with insect venom allergies. Ann Pharmacother 2006 40 699-703. [Pg.209]

Angiotensin converting enzyme inhibitors (ACE-I)—(oral therapy within 24 h after presentation)... [Pg.26]

Angiotensin converting enzyme inhibitors, atracurium, P-lactams, heparin, iron (parenteral), losartan, and streptokinase... [Pg.101]

Angiotensin converting enzyme inhibitors, azathioprine, mer-captopurine, mesalamine, sulfasalazine, sulfonamide antimicrobials, and tetracyclines... [Pg.118]

Other medications (e.g., angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and diuretics)... [Pg.155]

ACE-I, angiotensin-converting enzyme inhibitor Aid Ant, aldosterone antagonist ARB, angiotensin receptor blocker BB, beta-blocker CCBA, calcium channel blocking agent DirVaso, direct vasodilator. [Pg.22]

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 288(23) =2981-2997. [Pg.31]

To control risk factors and prevent major adverse cardiac events, statin therapy should be considered in all patients with ischemic heart disease, particularly in those with elevated low-density lipoprotein cholesterol. In the absence of contraindications, angiotensin-converting enzyme inhibitors should be considered in ischemic heart disease patients who also have diabetes melli-tus, left ventricular dysfunction, history of myocardial infarction, or any combination of these. Angiotensin receptor blockers... [Pg.63]

Formulate a monitoring plan for a patient with ST-segment elevation acute coronary syndrome receiving fibrinolytics, aspirin, unfractionated heparin, intravenous nitroglycerin, intravenous (3-blockers followed by oral P-blockers, an angiotensin-converting enzyme inhibitor, and a statin. [Pg.83]


See other pages where Converting enzyme inhibitors is mentioned: [Pg.55]    [Pg.234]    [Pg.240]    [Pg.129]    [Pg.132]    [Pg.212]    [Pg.349]    [Pg.262]    [Pg.174]    [Pg.9]    [Pg.94]    [Pg.327]    [Pg.191]    [Pg.1770]    [Pg.169]    [Pg.128]    [Pg.266]    [Pg.47]    [Pg.47]    [Pg.154]    [Pg.178]    [Pg.19]    [Pg.29]    [Pg.45]    [Pg.63]    [Pg.72]    [Pg.75]    [Pg.81]   
See also in sourсe #XX -- [ Pg.7 , Pg.44 ]




SEARCH



Angioedema angiotensin-converting enzyme inhibitor

Angiotensin I converting enzyme (ACE inhibitors

Angiotensin converting enzyme dual inhibitors

Angiotensin converting enzyme inhibitors (ACE

Angiotensin converting enzyme inhibitors actions

Angiotensin converting enzyme inhibitors effects

Angiotensin converting enzyme inhibitors heart failure management

Angiotensin converting enzyme inhibitors hypertensive renal disease

Angiotensin converting enzyme inhibitors prevention

Angiotensin converting enzyme inhibitors specific agents

Angiotensin converting enzyme inhibitors transporters

Angiotensin-converting enzyme (ACE) inhibitors for hypertension

Angiotensin-converting enzyme inhibitor

Angiotensin-converting enzyme inhibitor development

Angiotensin-converting enzyme inhibitors NSAIDs

Angiotensin-converting enzyme inhibitors adverse effects

Angiotensin-converting enzyme inhibitors adverse interactions

Angiotensin-converting enzyme inhibitors and hypertension

Angiotensin-converting enzyme inhibitors angioedema with

Angiotensin-converting enzyme inhibitors availability

Angiotensin-converting enzyme inhibitors binding

Angiotensin-converting enzyme inhibitors bradykinin

Angiotensin-converting enzyme inhibitors captopril

Angiotensin-converting enzyme inhibitors clearance

Angiotensin-converting enzyme inhibitors concepts

Angiotensin-converting enzyme inhibitors congestive heart failure

Angiotensin-converting enzyme inhibitors contraindications

Angiotensin-converting enzyme inhibitors contributions

Angiotensin-converting enzyme inhibitors coronary heart disease

Angiotensin-converting enzyme inhibitors cough with

Angiotensin-converting enzyme inhibitors diabetic nephropathy treatment

Angiotensin-converting enzyme inhibitors dosing

Angiotensin-converting enzyme inhibitors drug interactions

Angiotensin-converting enzyme inhibitors drug interactions with

Angiotensin-converting enzyme inhibitors drugs implication

Angiotensin-converting enzyme inhibitors enalapril

Angiotensin-converting enzyme inhibitors fosinopril

Angiotensin-converting enzyme inhibitors hyperkalemia with

Angiotensin-converting enzyme inhibitors hypertension treatment

Angiotensin-converting enzyme inhibitors in acute coronary syndromes

Angiotensin-converting enzyme inhibitors in heart failure

Angiotensin-converting enzyme inhibitors in hypertension

Angiotensin-converting enzyme inhibitors intravenous

Angiotensin-converting enzyme inhibitors lisinopril

Angiotensin-converting enzyme inhibitors metabolism

Angiotensin-converting enzyme inhibitors myocardial infarction

Angiotensin-converting enzyme inhibitors nephrotoxicity

Angiotensin-converting enzyme inhibitors patients

Angiotensin-converting enzyme inhibitors pharmacokinetics

Angiotensin-converting enzyme inhibitors ramipril

Angiotensin-converting enzyme inhibitors renal disease treatment

Angiotensin-converting enzyme inhibitors renal insufficiency

Angiotensin-converting enzyme inhibitors side effects

Angiotensin-converting-enzyme inhibitor ACEI)

Angiotension-converting enzyme inhibitors

Antihypertensive drugs angiotensin-converting enzyme inhibitors

Capoten Angiotensin converting enzyme inhibitor

Captopril converting enzyme) inhibitors

Cardiovascular drugs angiotensin-converting enzyme inhibitors

Converting enzyme

Endothelin-converting enzyme inhibitors

Enzyme inhibitors

Enzymes enzyme inhibitor

Hemodynamically-mediated kidney injury angiotensin-converting enzyme inhibitors

Inhibitors of angiotensin-converting enzyme

Interleukin-1/? converting enzyme inhibitors

Study Angiotensin-Converting Enzyme Inhibitors

© 2024 chempedia.info